Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DARA BioSciences, an oncology supportive care pharmaceutical company, has announced that the company signed a Medicare Part D Prescription Drug Program Reimbursement Agreement with Comprehensive Health Management providing formulary status for the WellCare Group of Companies for Soltamox (tamoxifen citrate) oral solution, the only liquid form of tamoxifen, used for the treatment and prevention of breast cancer.
Subscribe to our email newsletter
Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen. The inclusion of Soltamox on the Medicare Part D Formulary allows broad, affordable product access to WellCare members nationwide.
DARA BioSciences CEO and chief medical officer Dr David J Drutz noted the company continues to actively pursue ways to provide physicians and patients access to our synergistic portfolio of oncology supportive care products.
"Inclusion of Soltamox on WellCare’s National Medicare Part D Formulary opens the door for DARA to a vast network, and importantly, this Part D formulary coverage allows WellCare and DARA to better address the needs of breast cancer patients on tamoxifen," Dr Drutz added.
DARA holds exclusive US marketing rights to Soltamox, the only liquid form of tamoxifen, used for the treatment and prevention of breast cancer. Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen.